Perakizumab, being investigated by Novan, represents a important advance in the treatment against multiple fibrotic conditions. Distinct from traditional therapies, this agent carefully targets and inhibits TGF-beta https://bookmarklinking.com/story11254588/perakizumab-a-new-treatment-for-fibrosis-conditions